BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery

$BDX
Medical/Dental Instruments
Health Care
Get the next $BDX alert in real time by email

FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery.

Implant-based breast surgery is among the most common plastic surgery procedures performed each year in the U.S., and capsular contracture, a condition where the scar tissue naturally forming around the implant becomes unusually hard, causing pain and anatomical displacement, is its most frequent complication, with overall incidence ranging from 10% to 20%1-5. At advanced stages, CC necessitates treatment through surgical intervention, and when performed using conventional techniques, the risk of recurrence may be as high as 54%6. This multi-center Study of GalaFLEX LITE™ Poly-4-Hydroxybutyrate (P4HB) Scaffold in Treatment of Capsular Contracture after Breast Implant Augmentation (STANCE) is a pivotal study that aims to evaluate whether GalaFLEX LITE™ Scaffold, when used in breast revision surgery, decreases the likelihood of CC and or malposition. The trial further positions BD as a leader in advanced biomaterial science – driving transformative change in how tissue is reconstructed.

"This milestone marks a significant advancement in our efforts to achieve FDA Premarket Approval for our first breast indication for GalaFLEX LITE™ Scaffold and reinforces the company's commitment to improving patient outcomes through innovative technologies that reduce surgical complications," said Rian Seger, worldwide president of the BD Surgery business. "Our team has worked closely with the FDA to help address a critical medical complication arising from implant-based breast surgery, and the first patient treated brings us closer to delivering a much-needed solution."

GalaFLEX LITE™ Scaffold is engineered to conform to the desired anatomical structure and provide immediate strength and stability throughout the wound healing period7. It is made from P4HB, a fully absorbable, biologically-derived polymer with more than 10 years of clinical use supporting hernia repair and other plastic and reconstructive procedures where soft tissue weakness or deficiency exists.

"Participating in this trial underscores our commitment to innovation and providing the best evidence-based care for patients suffering from capsular contracture, offering them hope and solutions for the future," said Dr. Shawna Kleban, the board-certified plastic surgeon who performed the inaugural procedure. "This trial allows participants to help identify a solution for themselves and for future patients."

Dr. Caroline Glicksman, the study's National Principal Investigator from Sea Girt, New Jersey added, "As an early adopter of the P4HB technology, we are excited to see the potential benefits of GalaFLEX™ LITE Scaffold in improving patient outcomes in breast revision surgeries. This study is crucial in providing the data FDA requires for a specific breast indication that will advance our ability to deliver better solutions for breast surgery patients."

The following five sites are currently enrolling patients:

  • HKB Cosmetic Surgery (Various Locations, North Carolina) – Principal Investigator: Dr. Bill Kortesis; Sub-Investigators: Dr. Gaurav Bharti, Dr. Shawna Kleban, Dr. Brett Baker
  • Billington Plastic Surgery (St. Petersburg, Florida) – Principal Investigator: Dr. Alicia Billington
  • The Practice Plastic Surgery (Beverly Hills, California) – Principal Investigator: Dr. Kelly Killeen; Sub-Investigator: Dr. Lisa Cassileth
  • Plastic Surgery Institute of New York (New York, New York) – Principal Investigator: Dr. Matthew DelMauro; Sub-Investigator: Dr. Adam Shaffner
  • Newport Plastic and Reconstructive Surgery Associates (Newport Beach, California) – Principal Investigator: Dr. Hisham Seify
  • Essential Medical Research (Tulsa, Oklahoma) – Principal Investigator: Dr. John Tedesco

The trial is expected to enroll at least 250 patients across 40 investigative sites and aims to demonstrate the device's safety and efficacy in breast implant revision surgery to treat capsular contracture. BD is committed to scientific rigor and patient safety and aims to continue proactive FDA engagement in developing products that enhance women's health care.

STANCE Study

STANCE (NCT05945329) Study is an ongoing prospective, randomized, controlled, multi-center study to assess the safety and efficacy of GalaFLEX LITE™ scaffold in revision surgery for reduction of capsular contracture recurrence and/or malposition in implant-based breast augmentation patients versus patients undergoing conventional revision surgery with no supportive matrix or acellular dermal matrix (ADM). Patients will be randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care (no ADM or matrix placement). 

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Forward-Looking Statements

This press release contains certain forward-looking statements regarding the Premarket Approval clinical trial for GalaFLEX LITE™ Scaffold. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including, without limitation, clinical trial outcomes and progress, obtaining regulatory clearance and approval, including achieving FDA Premarket Approval for the first breast indication for GalaFLEX LITE™ Scaffold, competitive factors, including the development of new technologies or products by other companies, changes in healthcare practices and patient preferences, future regulatory and market conditions, or other factors listed in BD's 2024 Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. BD expressly disclaims any undertaking to update any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.

References

  1. Bachour, Y., Capsular Contracture in Breast Implant Surgery: Where Are We Now and Where Are We Going? Aesthetic Plast Surg, 2021. 45(3): p. 1328-1337.
  2. Brown, T., Plane Change Vs Capsulotomy: A Comparison of Treatments for Capsular Contraction in Breast Augmentation Using the Subfascial Plane. Aesthetic Plast Surg, 2021. 45(3): p. 845-850.
  3. Hasan, S., et al., Preliminary Outcomes of Hypochlorous Acid as an Adjunct for Pocket Irrigation in Revision Aesthetic Breast Surgery. Aesthet Surg J, 2021. 41(4): p. NP152-NP158.
  4. Calobrace, M.B., et al., Risk Factor Analysis for Capsular Contracture: A 10-Year Sientra Study Using Round, Smooth, and Textured Implants for Breast Augmentation. Plast Reconstr Surg, 2018. 141(4S Sientra Shaped and Round Cohesive Gel Implants): p. 20S-28S.
  5. Boyd, C.J., et al., Systematic Review of Capsular Contracture Management Following Breast Augmentation: An Update. Plast Reconstr Surg, 2023.1 Preclinical data on file. Results may not correlate to clinical outcomes.
  6. Hidalgo, D.A. and A.L. Weinstein, Surgical Treatment for Capsular Contracture: A New Paradigm and Algorithm. Plast Reconstr Surg, 2020. 146(3): p. 516-525.
  7. Preclinical data on file. Results may not correlate to clinical outcomes.

For more information about GalaFLEX LITE™ scaffold, please visit www.galateasurgical.com.

Contacts:

 



Media:                                                         

Investors:

Fallon McLoughlin                                     

Adam Reiffe

BD Corporate Communications                   

BD Investor Relations

201.258.0361                                             

201.847.6927 

Fallon.McLoughlin@bd.com                           

adam.reiffe@bd.com    

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-announces-milestone-in-clinical-trial-for-use-of-bioabsorbable-galaflex-lite-scaffold-in-breast-implant-revision-surgery-302406489.html

SOURCE BD (Becton, Dickinson and Company)

Get the next $BDX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BDX

DatePrice TargetRatingAnalyst
10/1/2024$255.00 → $275.00Neutral → Buy
Citigroup
5/30/2024$274.00Buy
Goldman
7/24/2023$305.00Mkt Perform → Outperform
Raymond James
5/30/2023$295.00Overweight
Morgan Stanley
5/5/2023$260.00 → $290.00Neutral → Overweight
Piper Sandler
4/12/2023$304.00Sector Weight → Overweight
KeyBanc Capital Markets
1/3/2023$250.00 → $290.00Neutral → Buy
BofA Securities
12/12/2022$221.00 → $250.00Sell → Neutral
Citigroup
More analyst ratings

$BDX
Press Releases

Fastest customizable press release news feed in the world

See more
  • BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery

    FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery. Implant-based breast surgery is among the most common plastic surgery procedures performed each

    $BDX
    Medical/Dental Instruments
    Health Care
  • BD to Present at Investor Healthcare Conferences

    FRANKLIN LAKES, N.J., Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: Citi's 2025 Unplugged Medtech and Life Sciences Access DayFebruary 27, 20258:45 a.m. Eastern Time Barclays 27th Annual Global Healthcare ConferenceMarch 11, 20258:30 a.m. Eastern Time The live webcasts of BD's presentations can be accessed from the BD investor relations website, investors.bd.com. A replay of the events will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is adv

    $BDX
    Medical/Dental Instruments
    Health Care
  • BD Reports First Quarter Fiscal 2025 Financial Results

    Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organicGAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectivelyBD completes $750 million share repurchase to date in FY25Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024. "We delivered strong operational performance in Q1, with

    $BDX
    Medical/Dental Instruments
    Health Care

$BDX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BDX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BDX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BDX
SEC Filings

See more

$BDX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    $BDX
    Medical/Dental Instruments
    Health Care
  • July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    $BDX
    Medical/Dental Instruments
    Health Care

$BDX
Leadership Updates

Live Leadership Updates

See more
  • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

    SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

    $BDX
    $FTRE
    $MRVI
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations
  • Revelyst Announces Chief Supply Chain Officer

    Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply

    $BDX
    $EMBC
    $VSTO
    Medical/Dental Instruments
    Health Care
    Ordnance And Accessories
    Industrials
  • Zeus Names New Chief Executive Officer

    Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /CNW/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.

    $BDX
    Medical/Dental Instruments
    Health Care

$BDX
Financials

Live finance-specific insights

See more
  • BD Reports First Quarter Fiscal 2025 Financial Results

    Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organicGAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectivelyBD completes $750 million share repurchase to date in FY25Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024. "We delivered strong operational performance in Q1, with

    $BDX
    Medical/Dental Instruments
    Health Care
  • BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value

    Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health careBiosciences and Diagnostic Solutions to realize its full market potential as differentiated leader in Life Sciences Tools and Diagnostics, with robust innovation pipeline and headroom for growth in key sectorsFRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announ

    $BDX
    Medical/Dental Instruments
    Health Care
  • BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25

    FRANKLIN LAKES, N.J., Jan. 28, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on March 31, 2025 to holders of record on March 10, 2025. The indicated annual dividend rate is $4.16 per share. The company also announced it repurchased $750 million in BD stock to date in fiscal 2025. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorization in 2021. The authorizations provide the c

    $BDX
    Medical/Dental Instruments
    Health Care

$BDX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more